• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Donna Young

Articles by Donna Young

FDA Wants Breast Cancer Stricken from Avastin's Label

Dec. 17, 2010
By Donna Young
WASHINGTON – The FDA Thursday said it wants the HER2-negative metastatic breast cancer indication stricken from the labeling of Genentech Inc.'s Avastin (bevacizumab), which gained accelerated approval in February 2008 as a first-line treatment in combination with paclitaxel for the disease.
Read More

New FDA Guidelines Encourage Co-Development

Dec. 16, 2010
By Donna Young
WASHINGTON – When two or more drugmakers are gathered in development's name, will there be love? The FDA thinks it's possible.
Read More

Study: D-Mab Delays Prostate Cancer Spread to Bones

Dec. 15, 2010
By Donna Young
Catching Wall Street by surprise, Amgen Inc. reported top-line Phase III results showing Xgeva (denosumab) improved median bone metastasis-free survival by 4.2 months in men with castrate-resistant prostate cancer (CRPC) vs. placebo – the first time a bone-targeted drug has delayed the spread of prostate cancer to the bones.
Read More

Infinity Extends Hedgehog, PI3K Pact with Mundipharma, Purdue

Dec. 14, 2010
By Donna Young
Infinity Pharmaceuticals Inc. is expected to garner an additional $110 million in 2012, on top of $65 million already banked this year and the $85 million anticipated in 2011, under an expanded deal with Mundipharma International Corp. Ltd., an independent European associated company of Purdue Pharmaceutical Products LP, to develop and commercialize IPI-926, Infinity's Smoothened (Smo) antagonist currently in Phase Ib/II testing, plus candidates arising from its phosphoinositol-3-kinase (PI3K) and discovery programs.
Read More

Appeals Court Hears Human Embryonic Stem Cell Case

Dec. 13, 2010
By Donna Young
WASHINGTON – A district judge's interpretation of the Dickey-Wicker Amendment was "fundamentally flawed" when the court ruled that human embryonic stem cell (hESC) research was illegal, and therefore, the order should be reversed, a government lawyer argued last week before a three-judge panel from the U.S. Circuit Court of Appeals for the District of Columbia.
Read More

XenoPort Prices Public Offering of 4M Shares

Dec. 10, 2010
By Donna Young
Shares of XenoPort Inc. tumbled 6.4 percent after the biotech priced a public offering of 4 million common shares at $7.15 per share, which was about 7.9 percent below Wednesday's closing price.
Read More

Will Contrave Vote Bode Well for All Obesity Drugmakers?

Dec. 9, 2010
By Donna Young
WASHINGTON – Investors in Orexigen Therapeutics Inc. Wednesday were not only bubbling over with excitement about an FDA panel's backing of the firm's obesity drug Contrave (naltrexone/bupropion) – with the company's stock rocketing as high as 129 percent – but shares of potential competitors Arena Pharmaceuticals Inc. and Vivus Inc. also were on fire, leaping as high as 20.5 percent and 19.5 percent, respectively.
Read More

FDA Panel Backs Orexigen's Contrave in Weight Loss

Dec. 8, 2010
By Donna Young
SILVER SPRING, Md. – Beating the odds, Orexigen Therapeutics Inc. won the backing of an FDA panel Tuesday for approval of the company's weight-loss drug Contrave (naltrexone/bupropion) – the only drug out of three recently reviewed at the agency to gain the Endocrinologic and Metabolic Drugs Advisory Committee's blessing.
Read More

Thera Inks Emerging Markets Deal with Sanofi for Egrifta

Dec. 7, 2010
By Donna Young

FDA Spotlights Contrave CV Risks; Orexigen Stock Tumbles

Dec. 6, 2010
By Donna Young
WASHINGTON – FDA drug reviewers in documents released Friday unsurprisingly focused on safety issues with Orexigen Therapeutics Inc.'s experimental weight-loss pill Contrave (naltrexone/bupropion), with the risks of adverse cardiovascular, psychiatric and cognitive events, along with seizures and increased serum creatinine among the agency's top concerns.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 107 108 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 9, 2025.
  • US flag, stock market chart, White House

    100 days of uncertainty

    BioWorld
    The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • NME Digest: Q1 2025

    BioWorld
    A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe